Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in diabetic macular edema: 2-year results from the Japan subgroup of the phase 3 YOSEMITE trial
Authors:
- Masahiko ShimuraMSMasahiko Shimura
- Junko SatoJSJunko Sato
- for the YOSEMITE and RHINE InvestigatorsFIfor the YOSEMITE and RHINE Investigators
Open Access
- 31 July 2024
- journal article
- research article
- Published by Springer Nature in Japanese Journal of Ophthalmology
- Vol. 68 (5) , 511-522
Abstract
Purpose: To evaluate the 2-year efficacy, durability, and safety of faricimab in patients with diabetic macular edema (DME) in the YOSEMITE Japan subgroup. Study design: YOSEMITE/RHINE (NCT03622580/NCT03622593) subgroup analysis: global, multicenter, randomized, double-masked, active-comparator–controlled, phase 3 faricimab trials. Methods: Patients were randomized 1:1:1 to intravitreal faricimab 6.0 mg every 8 weeks (Q8W) and per treat-and-extend (T&E) dosing, or aflibercept 2.0 mg Q8W. Outcomes were assessed through year 2 for the YOSEMITE Japan subgroup (N = 60) and the pooled YOSEMITE/RHINE global cohort (N = 1891). Results: In the YOSEMITE Japan subgroup, 21, 19, and 20 patients were randomized to faricimab Q8W, faricimab T&E, and aflibercept Q8W, respectively (632, 632, and 627 patients in the pooled YOSEMITE/RHINE cohort). Vision gains and anatomic improvements with faricimab at year 1 were maintained over 2 years and were generally consistent between groups. Mean best-corrected visual acuity changes from baseline at year 2 (weeks 92–100 average) for the YOSEMITE Japan subgroup were +12.5, +9.0, and +5.0 letters in the faricimab Q8W, faricimab T&E and aflibercept Q8W arms, respectively (+10.8, +10.4, and +10.3 letters in the pooled YOSEMITE/RHINE cohort). At week 96, 61.1% of the YOSEMITE Japan subgroup and 78.1% of the pooled YOSEMITE/RHINE cohort were on ≥ Q12W dosing. Faricimab was well-tolerated with a safety profile comparable with aflibercept. Conclusion: Faricimab up to Q16W offered durable vision gains and anatomic improvements up to 2 years in patients with DME in the YOSEMITE Japan subgroup. Outcomes were generally consistent with the pooled YOSEMITE/RHINE cohort.Keywords
Funding Information
- Chugai Pharmaceutical
- F. Hoffman-La Roche Ltd.
- Genentech
This publication has 19 references indexed in Scilit:
- Faricimab Treat-and-Extend for Diabetic Macular EdemaOphthalmology, 2023
- Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trialJapanese Journal of Ophthalmology, 2023
- Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in JapanJapanese Journal of Ophthalmology, 2022
- The Role of Angiopoietins in Neovascular Diabetes-Related Retinal DiseasesDiabetes Therapy, 2022
- Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomesGraefe's Archive for Clinical and Experimental Ophthalmology, 2022
- YOSEMITE and RHINEOphthalmology Science, 2021
- Review of clinical studies and recommendation for a therapeutic flow chart for diabetic macular edemaGraefe's Archive for Clinical and Experimental Ophthalmology, 2020
- Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individualsJapanese Journal of Ophthalmology, 2018
- Management of diabetic macular edema in Japan: a review and expert opinionJapanese Journal of Ophthalmology, 2017
- Clinical practice pattern in management of diabetic macular edema in Japan: survey results of Japanese retinal specialistsJapanese Journal of Ophthalmology, 2016